Cerus (NASDAQ: CERS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Cerus to similar businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, risk, earnings and profitability.

Insider & Institutional Ownership

58.1% of Cerus shares are owned by institutional investors. Comparatively, 57.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Cerus shares are owned by insiders. Comparatively, 11.2% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Cerus and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerus 0 0 4 0 3.00
Cerus Competitors 109 727 1024 10 2.50

Cerus currently has a consensus price target of $7.00, suggesting a potential upside of 86.67%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.49%. Given Cerus’ stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than its rivals.

Earnings & Valuation

This table compares Cerus and its rivals gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Cerus $39.28 million -$62.90 million -6.36
Cerus Competitors $1.67 billion $207.58 million 77.57

Cerus’ rivals have higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Cerus has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Cerus’ rivals have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.


This table compares Cerus and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerus -102.57% -140.75% -59.61%
Cerus Competitors -97.44% -91.73% -29.33%


Cerus rivals beat Cerus on 7 of the 12 factors compared.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Stock Ratings for Cerus Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Co. and related stocks with our FREE daily email newsletter.